Nrx Pharmaceuticals Stock Today
| NRXP Stock | USD 2.07 0.11 5.05% |
PerformanceOK
| Odds Of DistressAbout Average
|
NRX Pharmaceuticals is selling at 2.07 as of the 20th of March 2025; that is 5.05 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.03. NRX Pharmaceuticals has 47 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. The company has 16.92 M outstanding shares of which 1.15 M shares are now shorted by private and institutional investors with about 2.99 trading days to cover. More on NRX Pharmaceuticals
Moving against NRX Stock
NRX Stock Highlights
| CEO Secretary | Stephen Esq |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
NRX Pharmaceuticals (NRXP) is traded on NASDAQ Exchange in USA. It is located in 1201 Orange Street, Wilmington, DE, United States, 19801 and employs 14 people. NRX Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.21 M. NRX Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 16.92 M outstanding shares of which 1.15 M shares are now shorted by private and institutional investors with about 2.99 trading days to cover.
NRX Pharmaceuticals currently holds about 24.55 M in cash with (10.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Check NRX Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationNRX Pharmaceuticals maintains a total of 16.92 Million outstanding shares. NRX Pharmaceuticals secures 16.37 % of its outstanding shares held by insiders and 5.94 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NRX Ownership Details
NRX Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. NRX Pharmaceuticals market risk premium is the additional return an investor will receive from holding NRX Pharmaceuticals long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1023 | |||
| Jensen Alpha | 1.25 | |||
| Total Risk Alpha | 2.36 | |||
| Sortino Ratio | 0.1713 |
NRX Stock Against Markets
NRX Pharmaceuticals Corporate Management
| Suzanne Messere | Investor Relations | Profile | |
| Michael Abrams | Chief Officer | Profile | |
| Robert MIM | Chief Operations | Profile | |
| Michael Kunz | Gen Sec | Profile | |
| Molly Cogan | Sr Affairs | Profile |
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.